Navigation Links
Phase III study compared neoadjuvant therapy with lapatinib or trastuzumab for early breast cancer
Date:12/10/2010

SAN ANTONIO Researchers presented Phase III efficacy data from the GeparQuinto study, a head-to-head comparison of neoadjuvant lapatinib and trastuzumab in combination with chemotherapy for patients with early breast cancer, at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

"We had a primary goal to compare the standard anti-HER2 neoadjuvant combination of chemotherapy, trastuzumab, with the new combination of chemotherapy and lapatinib," said Michael Untch, M.D., head of the multidisciplinary breast cancer department at Helios Clinic in Berlin, Germany.

The GeparQuinto study was conducted at 85 centers throughout Germany and includes 2,500 patients, 550 of whom have HER2-neu-overexpressing breast cancer. This is the largest prospective patient cohort of chemo-targeted neoadjuvant therapy worldwide.

All patients received four cycles of 90 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide every three weeks, followed by four cycles of 100 mg/m2 docetaxel. They were randomly assigned to also receive concomitant 6 mg/kg trastuzumab every three weeks or 1,250 mg lapatinib per day throughout all cycles.

At baseline, patient characteristics were similar between the two groups, with both groups presenting a clinical median tumor size of 40 mm. The researchers also reported a similar number of patients in each group with T4a-c or T4d disease, bilateral, multifocal or multicentric disease, and estrogen receptor-negative and progesterone receptor-negative disease.

The last of the patients are currently undergoing surgery, and Untch will present histological and surgical outcome results for these patients at the symposium.

"After assessing response to neoadjuvant chemo-targeted therapy in patients with HER2 overexpressing tumors, we are following the patients from this study to see whether pathologic complete response at surgery is correlated to the outcome of the patients," he said.


'/>"/>

Contact: Jeremy Moore
jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Early safety results promising for Phase I/II trial of gene therapy treatment of hemophilia B
2. PAREXEL Completes 200 Patient Studies In Its Early Phase Units Over Three Years
3. OHSU Doernbecher Childrens Hospital conducts second phase of landmark Batten study
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. First X-ray lasers early success brings approval for next-phase facility
6. ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human])
7. Registration Opens for Next Testing Phase of IEEE Certified Biometrics Professional Program
8. First phase of pan-tropical forest mapping debuting at COP15
9. NIH funds new phase of high school-university research partnership
10. Scientists seek new emphases in Arctic climate change research
11. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... San Francisco, CA (PRWEB) , ... June 23, ... ... capture (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase ... DIA Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting ...
(Date:6/23/2016)... SAN FRANCISCO , June 22, 2016  Amgen ... platinum sponsorship of the QB3@953 life sciences ... improve human health. The shared laboratory space at QB3@953 ... startups overcome a key obstacle for many early stage ... As part of the sponsorship, Amgen launched two "Amgen ...
(Date:6/22/2016)... Research and Markets has announced the addition ... their offering. The global ... billion in 2013. The market is expected to grow at a ... 2020, increasing from $50.6 billion in 2015 to $96.6 billion in ... forecast period (2015 to 2020) are discussed. As well, new products ...
Breaking Biology Technology: